The effects of prostatic manipulation on prostate-specific antigen levels
| Autor: | Lonnie T. Klein, Franklin C. Lowe |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
PCA3
Male medicine.medical_specialty Prostate biopsy Urology medicine.medical_treatment Physical Exertion urologic and male genital diseases Management of prostate cancer Prostate cancer Antigen Medicine Humans Physical Examination Transurethral resection of the prostate Prostatectomy medicine.diagnostic_test business.industry Biopsy Needle Prostate Cystoscopy Prostate-Specific Antigen medicine.disease Response to treatment Prostatitis Prostate-specific antigen business |
| Zdroj: | The Urologic clinics of North America. 24(2) |
| ISSN: | 0094-0143 |
| Popis: | Prostate-specific antigen (PSA) has become the most widely used marker for the diagnosis and treatment of prostate cancer. 25 , 30 First isolated by Hara and associates 15 in seminal fluid and later identified in prostatic tissue by Wang and associates in 1979, 40 PSA is a serine protease produced by benign and malignant prostatic epithelial cells, and it serves to cause liquefaction of the seminal fluid. 30 Since 1987, PSA has been used in all aspects of prostate cancer management, including screening, diagnosis, staging, response to treatment, and identifying treatment failure. 26 Because PSA plays such a crucial role in the work-up and management of prostate cancer, any urologic intervention that may cause elevation of PSA has to be identified. It is well documented that certain procedures such as prostate biopsy, transurethral resection of the prostate (TURP), and other urologic procedures can cause elevation of the serum PSA. Since 1987, there have been several major studies that have looked at factors that might elevate PSA. This article provides a concise and current review on the most recent literature. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|